Palliative chemotherapy (CT) with or without cetuximab (CTX) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An Indian retrospective analysis

被引：0
|
作者：
Bahl, A. [1 ]
Choudhary, P. [1 ]
Bhatia, K. [1 ]
Singhla, S. [1 ]
Shrivastava, G. [1 ]
Bal, J. [2 ]
Anand, A. K. [2 ]
Chaturvedi, H. [3 ]
机构：
[1] Max Superspecial Hosp, Med Oncol, Delhi, India
[2] Max Superspecial Hosp, Radiat Oncol, Delhi, India
[3] Max Superspecial Hosp, Surg Oncol, Delhi, India
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
338P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis
    Bahl, Ankur
    Bhatia, Komal
    Choudhary, Pragati
    Singhla, Suhas
    Shrivastava, Gunjan
    Bal, Jaspriya
    Anand, Anil K.
    Chaturvedi, Harit M. Ch
    Dua, Bharat
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (05): : 955 - 962
  • [3] Retrospective analysis of the use of cetuximab (CTX) and paclitaxel (PTX) combination in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Soria Rivas, Ainara
    Rodriguez Garrote, Mercedes
    Olmedo Garcia, Maria Eugenia
    Lopez, Maria
    Garrido Lopez, Pilar
    Carrato, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] The role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN): A retrospective analysis
    Wakasugi, T.
    Enokida, T.
    Nakanome, A.
    Yamazaki, T.
    Okano, S.
    Tahara, M.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 95 - 95
  • [5] Palliative chemotherapy with cisplatin (C) and ifosfamide (I) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Fernández, A
    Mesía, R
    Montes, A
    Cardenal, F
    Montes, A
    García, M
    Dotor, E
    Muñoz, M
    Juan, A
    Monner, A
    Galiana, R
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S68 - S68
  • [6] Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Argiris, Athanassios
    Li, Shuli
    Savvides, Panayiotis
    Forastiere, Arlene A.
    Burtness, Barbara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Mehra, Ranee
    Egloff, Ann Marie
    Li, Shuli
    Yang, Donghua
    Wang, Lin
    Zhu, Fang
    Forastiere, Arlene A.
    Burtness, Barbara
    Argiris, Athanassios
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Weekly docetaxel as second-line (palliative) chemotherapy in recurrent/ metastatic head and neck squamous cell carcinoma (SCCHN)
    Koussis, H.
    Scola, A.
    Bergamo, F.
    Tonello, S.
    Jirillo, A.
    Basso, U.
    Pasetto, L. M.
    Sperandio, P.
    Donach, M. E.
    Monfardini, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck
    Machiels, Jean-Pascal
    Schmitz, Sandra
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (03) : 359 - 371
  • [10] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    [J]. ORAL ONCOLOGY, 2023, 147
12345